| Filed On | Filing |
|---|---|
| 30 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 28 Jul 2026 | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE |
| 28 Jul 2026 | 2ND QUARTER RESULTS |
| 28 Jul 2026 | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ |
| 24 Jul 2026 | ADMISSION TO TRADING |
| 24 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 22 Jul 2026 | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS |
| 20 Jul 2026 | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE |
| 17 Jul 2026 | AUDIT TENDER CONCLUSION |
| 17 Jul 2026 | CAMLIPIXANT PHASE III RESULTS UPDATE |
| 16 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 15 Jul 2026 | SC TO-T/A |
| 15 Jul 2026 | GSK COMPLETES ACQUISITION OF NUVALENT, INC |
| 14 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 13 Jul 2026 | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER |
| 10 Jul 2026 | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ |
| 10 Jul 2026 | SC TO-T/A |
| 09 Jul 2026 | DIRECTORATE CHANGE |
| 09 Jul 2026 | DIRECTOR/PDMR SHAREHOLDING |
Loading...
